Portfolio 1 - New Portfolio

John Bender

Portfolio 1
Individual Investor
Ranked #230,365 out of 753,381 TipRanks' Investors
Success Rate
53%
133 out of 253
profitable transactions
Average Return
10.42%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▼ 0.43%
6-Month Return▲ 3.33%
12-Month Return▲ 18.57%
YTD Return▲ 9.03%
Total Return▲ 107.75%

Best Trade

Opened at
Closed at
Gain▲ 538.65%

Bio

Income-focused Retirement Portfolio with speculative bio/pharma, EV and space positions

Performance

25.76%0-25.76%
▼ 1.87%
▲ 1.59%
▼ 2.90%
Jan 2024
▲ 14.08%
▲ 5.22%
▲ 10.93%
Feb 2024
▲ 5.05%
▲ 3.27%
▲ 1.33%
Mar 2024
▼ 12.40%
▼ 4.03%
▼ 7.50%
Apr 2024
▲ 11.46%
▲ 5.06%
▲ 7.40%
May 2024
▼ 2.25%
▲ 3.53%
▼ 4.35%
Jun 2024
▲ 25.76%
▲ 1.21%
▲ 8.73%
Jul 2024
▼ 5.09%
▲ 0.98%
▼ 3.32%
Aug 2024
TipRanks AverageS&P 500Investor Portfolio
▼ 1.87%▲ 1.59%▼ 2.90%
▲ 14.08%▲ 5.22%▲ 10.93%
▲ 5.05%▲ 3.27%▲ 1.33%
▼ 12.40%▼ 4.03%▼ 7.50%
▲ 11.46%▲ 5.06%▲ 7.40%
▼ 2.25%▲ 3.53%▼ 4.35%
▲ 25.76%▲ 1.21%▲ 8.73%
▼ 5.09%▲ 0.98%▼ 3.32%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Atara Biotherapeutics
▼ 94.80%
4
Close
Feb 18, 2024
Agenus
▼ 83.14%
3
Close
Feb 18, 2024
Carnival
▼ 5.19%
4
Close
Feb 18, 2024
ImmunoGen
▲ 538.65%
4
Close
Feb 18, 2024
Caribou Biosciences
▼ 29.06%
2
Close
Feb 18, 2024
Crinetics Pharmaceuticals
▲ 104.88%
2
Close
Feb 18, 2024
Cyclo Therapeutics
▼ 6.88%
2
Close
Feb 18, 2024
Precision BioSciences
▼ 71.79%
3
Close
Feb 18, 2024
Capital Southwest
▲ 45.75%
2
Close
Feb 18, 2024
Axsome Therapeutics
▲ 105.56%
3
Close
Feb 18, 2024
Spyre Therapeutics
▼ 9.83%
2
Close
Feb 18, 2024
Allogene Therapeutics
▼ 38.85%
3
Close
Feb 18, 2024
Alpine Immune Sciences
▲ 428.93%
2
Close
Feb 18, 2024
Altimmune
▲ 23.95%
3
Close
Feb 18, 2024
ProShares MSCI Transformational Changes ETF
▲ 31.56%
2
Close
Feb 18, 2024
ARK Innovation ETF
▲ 31.48%
3
Close
Feb 18, 2024
Arcutis Biotherapeutics
▼ 41.09%
3
Close
Feb 18, 2024
Astra Space
▼ 79.27%
3
Close
Feb 18, 2024
Anavex Life Sciences
▼ 53.41%
2
Close
Feb 18, 2024
Ares Capital
▲ 17.86%
3
Close
Feb 18, 2024